Sulforaphane Metabolic Health Randomized Trial: What the Evidence Says

Quick Answer

Sulforaphane Metabolic Health Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The positive symptoms manifest as hallucinations, delusions, and disorganized speech or behavior, while the negative symptoms consist of cognitive impairment with reduced motivation and expressiveness factors that affect memory and mental processing. [Kassar Omar (2025); evidence level 1]
• Patients with schizophrenia have a mortality rate of 2-3-fold compared to healthy people, with a reduced expected life of 10-20 years. [Kassar Omar (2025); evidence level 1]
• MG has been implicated in processes such as insulin resistance, vascular injury, neurodegeneration, and cellular senescence, highlighting its central role in disease-associated metabolic imbalance. [Khan Masood Alam (2026); evidence level 4]
• In this pathway, MG reacts with reduced glutathione (GSH) to form a hemithioacetal intermediate, which is subsequently converted by Glo1 into S-D-lactoylglutathione, representing the rate-limiting step of MG detoxification. [Khan Masood Alam (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For sulforaphane metabolic health randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Kassar Omar (2025). Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. DOI: 10.1186/s12888-025-07515-7. PMCID: PMC12581406. PMID: 41184790. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12581406/
• Khan Masood Alam (2026). Targeting Glyoxalase-1 Pathway with Natural Compounds: A Translational Strategy to Reduce Dicarbonyl Stress and Prevent Chronic Diseases. DOI: 10.3390/life16050822. PMCID: PMC13208436. PMID: 42195377. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13208436/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.